T he coagulation cascade was first described in the 1960s as consisting of two distinct pathways, the intrinsic and extrinsic, joined to a common pathway. Figure 1 shows this simplified version, known as the waterfall/cascade model of the coagulation system. Since then, our understanding of hemostasis has greatly expanded, revealing an extremely complex, intertwined system of clotting factors, proteins, anticoagulant/fibrinolytic pathways, and platelets intricately checked by a multitude of feedback loops. The modern view of coagulation now is largely cell-based and organizes clot formation into initiation, amplification, and propagation. 1 Still, the simple old two-pathway model is beneficial in terms of helping us understand what abnormal coagulation tests mean. This chapter will use the waterfall/cascade model to describe and examine several causes of perioperative coagulopathy, and discuss the drugs used to treat these abnormalities.
PREOPERATIVE PERIOD
The main concern during the preoperative period is to accurately screen patients for a preexisting bleeding disorder before surgery. Patients can have congenital abnormalities or acquired bleeding disorders from coexisting diseases, transfusions, medications, or herbal remedies. The best means of detecting a hemorrhagic diathesis is by a thorough history and physical. Some screening preoperative questions that may help elucidate a bleeding disorder are listed in Table 1 .
Most patients with congenital coagulation abnormalities are identified early in life, and present for surgery with established diagnoses. Patients with hemophilia, von Willebrand disease, and platelet disorders usually need treatment before, during, and after surgery. As hematologists are often involved with their care, treatment for these abnormalities will not be discussed in this chapter.
The more pressing question is: what does an abnormal coagulation test mean for the patient scheduled for surgery tomorrow? Preoperative bleeding abnormalities are best classified based on the abnormal laboratory value: prothrombin time (PT) or activated partial thromboplastin time (aPTT). PT abnormalities are associated with factors involved in the extrinsic and common pathways, which include FII, FV, FVII, FX, or fibrinogen. These factor deficiencies are associated with liver disease, vitamin K deficiency, or warfarin effect. Activated PTT abnormalities can be associated with deficiencies or inhibitors of factors in the intrinsic pathway, which include FVIII, FIX, FX, FXI, or FXII. Diseases often associated with these deficiencies include hemophilia A (VIII), hemophilia B (IX), lupus anticoagulant (LA), or heparin effect (Figure 1) .
These laboratory values, wheres frequently helpful for diagnosis, are not good predictors of intraoperative bleeding. For instance, although it is clear that deficiencies of each of the factors in the intrinsic pathway could have equally long aPTT values, there are dramatically different hemorrhagic risks for each. Deficiencies of FXII are not associated with significant hemorrhage, whereas deficiencies of FXI might or might not be associated with hemorrhage, 2 and deficiencies of FVIII and FIX are consistently associated with hemorrhage. To confuse matters more, the LA frequently leads to an increased aPTT, but the clinical presentation is typically that of thrombosis as opposed to bleeding. Owing to this lack of predictability for bleeding, preoperative coagulation tests are not recommended for healthy ASA I or ASA II patients with negative bleeding histories. 3 An algorithm for further preoperative work-up for an abnormal PT or aPTT, and a positive bleeding history is shown in Figure 2 . If the work-up for LA is positive, then the patient may proceed to the operating room, but hematology should be involved postoperatively due to the increased risk for thrombosis. Patients with elevated PT or aPTT with negative LA need to undergo work-up for factor inhibitors or deficiencies. If levels are low or an inhibitor is present, then further hematology work-up is required. Patients with a positive bleeding history, but normal PT and aPTT, should have a more extensive hematology consultation. In this instance, low or dysfunctional platelets, mild deficiency of von Willebrand factor, vascular disorders, and, rarely, FXIII deficiency should be considered.
INTRAOPERATIVE PERIOD
There are really only two major causes of intraoperative bleeding. The first and most common is bleeding at the operative site, which needs to be corrected surgically. The second is nonsurgical or medical bleeding, or failure of the hemostatic pathways. Causes for this failure are shown in Table 2 .
The mainstays of massive blood loss management include replacement of red cells, platelets, clotting factors, and fibrinogen. Avoidance of hypothermia, correction of acidosis/shock, and frequent checking of laboratory values, to help guide transfusions and electrolyte replacements, are necessary. A basic laboratory profile in the operating room should include hematocrit, platelet count, PT, aPTT, and fibrinogen level.
For trauma patients, the evaluation should also focus on the degree of shock or tissue hypoperfusion. Although the classical teaching of acute traumatic coagulopathy focused on consumption, dilution, and hypothermia, more recent findings strongly support the central role of shock, which can lead to activation of protein C, systemic anticoagulation, and hyperfibrinolysis. 4, 5 Brohi et al., 4 found that trauma patients with base deficits greater than 6 mEq/L had a 20% chance of developing coagulopathy, compared with 2% risk for patients with base deficits less than 6 mEq/L. Current management of acute traumatic coagulopathy focuses on early blood products and replacement of coagulation proteins rather than crystalloid resuscitation. The ratio of fresh frozen plasma (FFP) and packed red blood cells (PRBC) is of particular importance. Duchesne et al., 6 showed, in a retrospective review of 2746 trauma patients, that a 1:1 ratio of FFP:PRBC had a significantly (Po 0.0001) decreased risk of mortality as compared with a 1:4 ratio. Borgman et al., 7 reviewed 246 massive transfusion patients. They supported the results by showing a significant decrease in mortality when the ratio stayed closer to 1:1 as compared with 1:2.5 or 1:8. Other factors that may be of importance include the ratio of platelets to PRBC. Holcomb et al. 8 showed improved 30-day survival with high FFP:RBC ratios and high platelet:RBC ratios. The patients in the high ratio groups had decreased intensive care unit stay, ventilator days, and hospital stay. Whether we should apply the same transfusion ratios for surgical patients in the operating room remains to be determined, but the underlying pathophysiologic concerns seem similar.
Other than hemodilution, hypothermia, and acidosis, the remaining causes of medical bleeding are fibrinolysis and disseminated intravascular coagulation (DIC). DIC is a derangement of the coagulation system leading to clotting and then fibrinolysis. This is difficult to diagnose during surgery, particularly since there is no pathognomonic laboratory test. Surgical bleeding alone can cause an elevated PT, low fibrinogen levels, and low platelet counts. Distinguishing between primary fibrinolysis and DIC by laboratory values intraoperatively is challenging. The diagnosis will often depend on the clinical scenario. D-dimers can be ordered, but the results will not be available quickly. The first goal in treatment of DIC is to correct the primary disorder, if possible, and then replace fibrinogen, platelets, and coagulation factors as necessary. Heparin therapy is not universally accepted in the treatment of DIC. The decision to use heparin, especially intraoperatively, should be discussed with the surgical team and the hematologists.
Treatment
Fortunately, there are some pharmacologic interventions available for use during massive blood loss. These can be divided mainly into two categories: drugs that increase clotting and drugs that decrease clot breakdown. Overall, although it appears that the medications may reduce blood loss, there has been lack of evidence showing improved mortality and morbidity.
Recombinant Factor VIIa
Recombinant factor (rFVIIa, Novoseven) was originally developed for the treatment of patients with hemophilia A or B with antibodies to FVIII and FIX, respectively. 9 Now, wider applications of this drug also include treatment of patients with other factor deficiencies (FVII, FV, FXI), and patients with qualitative or quantitative platelet defects (Glanzmann thrombasthenia, Bernard-Soulier syndrome). 10 Recombinant FVIIa enhances hemostasis due to the additional generation of thrombin (Figure 3 ). In the tissue factor-dependent or extrinsic system, rFVIIa binds to tissue factor at the site of vessel injury, causing activation of FX. In the tissue factor-independent or intrinsic system, rFVIIa binds to the surface of the activated platelet, directly activating FX. This explains why rFVIIa can overcome FVIII and FIX deficiencies in patients with hemophilia. Both mechanisms result in a ''burst'' of thrombin and fibrin generation, which leads to clot formation. A key point, however, is that there must be sufficient platelets and fibrinogen for rFVIIa to effectively generate the thrombin burst. Other important factors that should also be corrected are temperature, acid/base status, and calcium to improve the responsiveness to the drug. 10 A growing number of case reports suggest that this agent may be effective in various ''off-label'' indications. It has been used to control intractable bleeding when other efforts have failed to work. Its use has also progressed from rescue therapy to prophylactic therapy in surgical situations with expected heavy blood loss, such as complex cardiac surgeries or liver transplantations.
In a randomized controlled trial (RCT) involving 36 patients undergoing radical prostatectomy, patients were randomized to placebo, rFVIIa at 20, or 40 mcg/kg.
11 Patients receiving rFVIIa had a mean blood loss that was statistically significantly lower than the control group. In trauma patients, the use of rFVIIa reduced the need for massive blood transfusions (defined as 4 20 units) from 33% in the control group down to 14% in the treatment group. 12 Although the results for penetrating trauma were also promising, the data did not reach statistical significance. Efficacy, dosage, and safety of rFVIIa use during cardiac surgery remain unclear, particularly considering the higher risk and catastrophic result of thromboembolic events in this patient population. 10 Researchers have also gained experience with the use of rFVlIa in intracranial hemorrhages. So far, the data show that the drug decreases the size of the hemorrhage as assessed by volume on serial head computed tomographic scans. 13 The study was repeated in a phase 3 trial. 14 There, again, was decreased growth in the volume of the intracranial hemorrhage, but mortality was similar in both groups, and the incidence of severe disability at 90 days was not improved in the treatment groups. Two meta-analyses and one Cochrane report have attempted to summarize all the data. [15] [16] [17] Depending on inclusion criteria, most included between 7 and 13 trials. All together, only about 700 patients have been enrolled in trials involving the prophylactic use of rFVIIa during liver transplantation, liver resection, prostatectomy, repair of pelvic trauma, and cardiac surgery. Approximately, 1200 patients have been enrolled in studies looking at the therapeutic use of rFVIIa. The underlying etiologies for the therapeutic use of rFVIIa have been quite varied, and include stem-cell transplant, dengue fever, trauma, upper gastrointestinal bleeding, and intracranial hemorrhage. If all the trials are analyzed together, there is a slight reduction in the number of patients that needed PRBC transfusions with the prophylactic use of rFVIIa. The effect is mostly from the use of high dose rFVlIa (450 mcg/kg) and not low dose treatments. In the studies that looked at the use of rFVIIa therapeutically, there was no significant difference in the number of patients transfused between the treated and not treated groups.
Aside from reduced transfusion needs, the endpoints of real interest should be morbidity and mortality. Mortality data have been unclear, since often rFVIIa is used as a last ditch effort. In the meta-analysis, there were only 14 deaths out of 507 patients. [15] [16] [17] With so few deaths, the confidence interval was quite wide, and so there appeared to be no statistically significant decrease in mortality.
At this point, the data does not favor the prophylactic use of rFVlla, but also cannot show definitive harm from its use.
As the use of rFVlla increases, there have been more reports of morbidity from thromboses. O'Connell et al. 18 looked at the Food and Drug Administration (FDA) adverse event database, a voluntary reporting system. From the 431 reports involving rFVIIa, 168 described thrombotic complications. ''Off label'' usage accounted for 151 of these reports. Thirty-six of the 50 deaths reported were attributed to the thromboembolic event. The rate of complication is still uncertain because the denominator is unclear. Patients with procoagulant diseases (cancer, infections, h/o thromboembolic events, and receiving procoagulant drugs) were usually excluded from the studies, so the actual risk of thromboembolic events could potentially be higher as drug use increases in the general surgical and critically ill patient population. From the intracranial hemorrhage data, 13, 14 the incidence of thrombosis was higher, especially for arterial events (myocardial infarctions and cerebrovascular accidents), in patients who received 80 mcg/kg of rFVIIa.
At this point, the data does not favor the prophylactic use of rFVlla, but also cannot show definitive harm from its use. Considering that no RCT has been able to demonstrate a significant benefit in terms of intensive care unit stay, hospital stay, or mortality, the financial burden of this drug needs to be weighed against the cost/benefit of transfusing fewer blood products. Each clinician will have to consider the risk of thromboembolic events against continued bleeding for each individual patient. More RCTs are necessary before a definitive statement can be made about the efficacy, safety, and dosage recommendations of rFVIla.
Antifibrinolytics
Antifibrinolytics, like aprotinin, tranexamic acid, and epsilon-aminocaproic acid, fall into the category of drugs that decrease clot breakdown. These can be given if fibrinogen levels remain low, and a mechanism for primary fibrinolysis seems likely. Both tranexamic acid and epsilonaminocaproic acid are synthetic lysine derivatives that reversibly bind to plasminogen, preventing fibrinolysis. 19 Aprotinin is a serine protease inhibitor, and was widely used in cardiopulmonary bypass cases to reduce blood loss and transfusions. However, it is no longer available (except by special request) due to the data attributing higher risks of stroke, myocardial infarction, renal failure, and death to this drug. 20 Antifibrinolytic drugs have been recommended in cardiac surgery to reduce blood loss during and following cardiopulmonary bypass. These drugs have also gained popularity in noncardiac surgeries. Although blood loss is reduced in most studies, data showing a decrease in the number of blood transfusions is inconsistent. Some of the heterogeneity is due to different dosing schedules; the trials have a three-fold difference in loading dose. These drugs may also have efficacy in liver transplantation and orthopedic surgery, but the trials are small. Kagoma et al. 19 published a systematic review of randomized trials evaluating the use of antifibrinolytics (tranexamic acid, epsilon aminocaproic acid, and aprotinin) in total knee and total hip replacement surgeries. This analysis, however, included great variability in the type and dose of antifibrinolytics across the studies, so a definitive conclusion was not possible. More adequately powered studies are necessary to elucidate the role of antifibrinolytics in these operations.
POSTOPERATIVE CAUSES OF ABNORMAL COAGULATION
In the postoperative period, usually the deficiency of clotting factors, platelets, and red cells begin to resolve, unless there is ongoing surgical blood loss. Now, the imbalance of procoagulant and anticoagulant agents increases the risk for prothrombotic complications. Standard of care is to institute thromboembolic prophylaxis in surgical patients.
Heparin is the usual drug of choice, but it has many drawbacks. It is an indirect thrombin inhibitor and, therefore, is effective on free thrombin only, and has limited inhibition of clot-bound thrombin. It requires antithrombin as a cofactor, which leads to wide interindividual variability. The most devastating side effect of heparin is its ability to form a complex with platelet factor 4 (PF4), which can then generate formation of heparin-PF4 antibodies. In a subset of patients, the immunoglobulin G (IgG) antibodies can bind to the Fc receptor on the platelets, which leads to activation and consumption of platelets, and thrombus generation 21 ( Figure 4 ). This can lead to heparin-induced thrombocytopenia (HIT) with thrombosis, the most dangerous manifestation.
The diagnosis of HIT depends on a high clinical suspicion. Clinical suspicion should be increased if there is a moderate platelet decline more than 5 days after first exposure to heparin, because it takes about 5 days to generate the IgG antibodies. The time frame can be much shorter on heparin reexposure since the patient already has antibodies. Patients are unlikely to have HIT if platelet counts are very low (o 15 Â 10 9 /L). Risk factors for HIT are duration of therapy more than 5-7 days, unfractionated heparin versus low molecular weight heparin use (5% vs. 0.5%, respectively), surgical patients more than medical patients, bovine heparin rather than porcine heparin, and female patients more frequently than male patients. 22 Detection of HIT antibodies (enzyme-linked immunosorbent assay) is not sufficient for the diagnosis of HIT. A functional assay must be performed to detect the presence of plasma antibodies that result in platelet activation. The serotonin-release assay takes donor platelets with radiolabeled serotonin and adds them to patient plasma. The addition of heparin results in platelet activation and release of radiolabeled serotonin if HIT is present. While awaiting test results, heparin should be discontinued and a nonheparin anticoagulant instituted, even though there is thrombocytopenia. Simple discontinuation of heparin, without the provision of alternate anticoagulants has been associated with subsequent severe and fatal thrombotic complications if the patient has HIT with thrombosis. Warfarin should be avoided as the first agent due to the initial drop in protein C, which makes the patient hypercoagulable. Platelet transfusions should also be avoided unless there is active bleeding, as it just adds more ''fuel to the fire.'' 21, 22 Direct Thrombin Inhibitors (DTIs) DTIs, initially isolated from the saliva of leeches, have been developed for use as anticoagulants in patients with HIT. Most DTIs are relatively short acting and predictable. DTIs inhibit free and clot-bound thrombin, and are independent of antithrombin. The drugs are not bound to plasma proteins nor neutralized by PF4. Dosing can be monitored by following PTT or activated clotting time (ACT) in the operating room. 23 The drawback for these drugs is that there are no specific reversal agents. Dialysis may be effective, and rFVIla has shown some efficacy in animals and in healthy volunteers ex vivo. 24 One DTI, melagatran, and its oral formulation, ximelagatran, were removed from the market due to hepatotoxicity.
Lepirudin
The first drug approved by the FDA was lepirudin. It can lead to frequent bleeding complications, and its elimination is dependent on renal function. Half-life can be prolonged to 4-5 days in dialysis-dependent patients. There is no reversal agent like protamine for lepirudin. Hemodialysis and hemofiltration may be effective, but the data are limited. More than half the patients treated with lepirudin for more than 5 days develop antihirudin antibodies. These are not neutralizing antibodies, but may actually enhance drug potency, perhaps by delaying its clearance from the circulation. As a result, the aPTT needs to be monitored on a regular basis in these patients. Severe anaphylaxis is rare, but has been reported, and appears to be more common in patients with previous exposure.
Argatroban
Argatroban has a 45-minute half-life, and it is cleared by the liver, so no dose adjustments are needed in patients with low glomerular filtration rate. It is less immunogenic than lepirudin, but it does increase the international normalized ratio, which may be a factor when initiating Coumadin. Like all DTIs, dose should be titrated to aPTT (1.5-3 Â normal) or ACT. The FDA approved this drug as an anticoagulant for prophylaxis or treatment of thrombosis in patients with HIT and for percutaneous coronary intervention in patients with or at risk for HIT. There are also a few reports of the successful use of argatroban in ischemic stroke, hemodialysis, continuous renal replacement therapy, and peripheral vascular surgery. [25] [26] [27] Bivalirudin Bivalirudin has a 25-minute half-life, and it is 80% cleared by proteolysis and 20% renally cleared. Unlike argatroban, it needs to be dosed for glomerular filtration rate, and it only causes a slight increase in international normalized ratio. The dose should be titrated to aPTT (1.5-3 Â normal) or ACT. The FDA approved this drug as an anticoagulant for percutaneous transluminal coronary angioplasty in patients with unstable angina 28 and for percutaneous coronary intervention. Other reported uses of bivalirudin include cardiopulmonary bypass, vascular surgery, and neuroendocrine procedures. Table 3 summarizes a comparison between the different DTIs.
Regional Anesthesia
There is not much data on the use of these new anticoagulants with regional anesthesia. Only a few case reports relating to spontaneous intracranial hemorrhages have been published in the literature. Broad clinical experience with these drugs and neuraxial techniques does not exist. Most recommendations, if there are any, are based exclusively on the pharmacokinetics of the drugs themselves. 29 In fact, the American Society of Regional Anesthesia and Pain Management at their last consensus conference declined to make a statement regarding the use of epidural catheters for patients receiving DTIs due to the lack of information. 30 
SUMMARY
The modern view of coagulation is of a highly complex system with multiple cofactors and enzymes divided into the initiation, amplification, and propagation phase of clot formation. The older view of an intrinsic and extrinsic pathway, although greatly simplified, is still useful because it illustrates what the coagulation tests (PT/PTT) are measuring. Bleeding diatheses in the perioperative period are easier to discuss when we divide the differential into the preoperative, intraoperative, or postoperative periods. Several new drugs that either increase clotting or increase anticoagulation have been introduced, and many more are due on the market. It is the responsibility of anesthesiologists to understand the mechanisms of action of these agents and know how to safely use them in the perioperative period. 
